Humana Stock Falls as Q2 Report Holds Adjusted Outlook and Cuts GAAP EPS View
Humana shares fell after the insurer kept its adjusted profit outlook flat and lowered its GAAP earnings-per-share view for the year.
Medium impactLong-term
You are viewing a historical snapshot of United States (NYSE / Nasdaq). These figures are a preview to show what TradeTidings covers. Live, continuously updated United States sentiment and stock impact is a Pro feature.
Get live United States data with ProHealth Care
+0.19Positive22 stories · last 90 days
Net news sentiment 0.19 (Positive) across 22 stories · last 90 days. Not a price prediction.
What's driving Health Care now
Over the last 90 days, Health Care shows 13 positive, 1 neutral and 8 negative news signals across its constituents. The auto-generated sector insight (top drivers with direction + rationale) appears here once the analysis worker has processed enough items.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Sentiment timeline
How news sentiment on the Health Care sector has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
Not enough day-by-day history for the Health Care sector yet. It builds as news is analysed — try the Week or Month view.
Constituent stocks
ABBV
AbbVie
0 · 0 · 22 stories
ABT
Abbott Laboratories
Health CareNo coverage yet
AMGN
Amgen
Health CareNo coverage yet
BMY
Bristol Myers Squibb
Health CareNo coverage yet
CVS
CVS Health
Health CareNo coverage yet
DHR
Danaher Corporation
0 · 0 · 11 story
GILD
Gilead Sciences
Health CareNo coverage yet
ISRG
Intuitive Surgical
0 · 0 · 11 story
JNJ
Johnson & Johnson
3 · 0 · 03 stories
LLY
Lilly (Eli)
1 · 0 · 34 stories
MDT
Medtronic
Health CareNo coverage yet
MRK
Merck & Co.
1 · 0 · 01 story
PFE
Pfizer
Health CareNo coverage yet
TMO
Thermo Fisher Scientific
1 · 0 · 01 story
UNH
UnitedHealth Group
Health CareNo coverage yet
A
Agilent Technologies
1 · 0 · 01 story
ALGN
Align Technology
Health CareNo coverage yet
ALNY
Alnylam Pharmaceuticals
Health CareNo coverage yet
BAX
Baxter International
Health CareNo coverage yet
BDX
Becton Dickinson
Health CareNo coverage yet
BIIB
Biogen
1 · 0 · 01 story
BSX
Boston Scientific
Health CareNo coverage yet
CAH
Cardinal Health
Health CareNo coverage yet
CI
Cigna
Health CareNo coverage yet
CNC
Centene Corporation
Health CareNo coverage yet
COO
Cooper Companies (The)
Health CareNo coverage yet
COR
Cencora
Health CareNo coverage yet
CRL
Charles River Laboratories
Health CareNo coverage yet
DGX
Quest Diagnostics
2 · 0 · 02 stories
DVA
DaVita
Health CareNo coverage yet
DXCM
Dexcom
Health CareNo coverage yet
ELV
Elevance Health
1 · 0 · 01 story
EW
Edwards Lifesciences
Health CareNo coverage yet
GEHC
GE HealthCare
Health CareNo coverage yet
HCA
HCA Healthcare
Health CareNo coverage yet
HSIC
Henry Schein
Health CareNo coverage yet
HUM
Humana
0 · 0 · 11 story
IDXX
Idexx Laboratories
Health CareNo coverage yet
INCY
Incyte
Health CareNo coverage yet
IQV
IQVIA
Health CareNo coverage yet
LH
Labcorp
Health CareNo coverage yet
MCK
McKesson Corporation
Health CareNo coverage yet
MRNA
Moderna
Health CareNo coverage yet
MTD
Mettler Toledo
Health CareNo coverage yet
PODD
Insulet Corporation
Health CareNo coverage yet
REGN
Regeneron Pharmaceuticals
Health CareNo coverage yet
RMD
ResMed
Health CareNo coverage yet
RVTY
Revvity
Health CareNo coverage yet
SOLV
Solventum
Health CareNo coverage yet
STE
Steris
Health CareNo coverage yet
SYK
Stryker Corporation
Health CareNo coverage yet
TECH
Bio-Techne
Health CareNo coverage yet
UHS
Universal Health Services
Health CareNo coverage yet
VEEV
Veeva Systems
1 · 1 · 02 stories
VRTX
Vertex Pharmaceuticals
Health CareNo coverage yet
VTRS
Viatris
Health CareNo coverage yet
WAT
Waters Corporation
Health CareNo coverage yet
WST
West Pharmaceutical Services
1 · 0 · 01 story
ZBH
Zimmer Biomet
Health CareNo coverage yet
ZTS
Zoetis
Health CareNo coverage yet
Latest Tidings
The most recent stories affecting Health Care, across all of our coverage.
Biogen Stock in Focus as Q2 Earnings Beat and New Drugs Lift Guidance
Biogen beat second-quarter earnings estimates and raised its 2026 guidance as newer drugs helped drive sales beyond its legacy franchises.
Medium impactShort-term
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to End Its Marathon Legal Fight
Johnson & Johnson has proposed a $5.5 billion settlement to resolve years of talc litigation, replacing an open-ended legal risk with a fixed, known cost.
Medium impactLong-term
AbbVie Stock: Epcoritamab Trial Setback Raises Questions on Blood Cancer Pipeline
AbbVie hit a setback in a clinical trial for epcoritamab, a blood cancer drug it counts on to help offset declining Humira sales.
Medium impactLong-term
Agilent Technologies Stock: FDA Clears New Opdivo Companion Diagnostic Test
Agilent won FDA clearance for a new companion diagnostic test used alongside the cancer drug Opdivo, supporting its diagnostics business.
Medium impactLong-term
Eli Lilly Stock: FDA Filing Delay for Next-Gen Weight-Loss Drug Retatrutide
Eli Lilly has pushed back the FDA filing for retatrutide, its next generation weight loss drug candidate meant to follow Zepbound and Mounjaro.
Medium impactShort-term
AbbVie Stock: Epcoritamab Misses Key Survival Goal in Phase 3 Lymphoma Trial
AbbVie's epcoritamab failed to meet a key overall survival goal in a Phase 3 trial for a form of lymphoma, a setback for one of its pipeline growth drivers.
Medium impactLong-term
Quest Diagnostics Stock: Earnings Beat Reinforces Its Defensive Profitability Story
Quest Diagnostics topped profit expectations in its latest quarter, adding evidence to the case that its lab-testing business holds up well even when the broader economy wobbles.
Medium impactShort-term
Danaher Stock Tries to Stabilize After a Sharp Post-Earnings Selloff
Danaher shares are attempting to stabilize after tumbling on the back of its latest quarterly results, as investors weigh how much of the drop reflects a genuine business slowdown.
Medium impactShort-term
Veeva Systems Stock: Raised 2027 Outlook and Strong Q2 Earnings
Veeva Systems posted a strong quarter and raised its outlook for fiscal 2027, a signal that demand for its life-sciences software keeps growing faster than the broader enterprise software market.
Medium impactLong-term
Quest Diagnostics (DGX) Stock: Baird Raises Price Target to $255
Baird raised its price target on Quest Diagnostics to $255, pointing to confidence in the lab-testing giant's volume growth and expanding advanced diagnostics business.
Low impactShort-term
Johnson & Johnson Stock: Early Phase 3 Win in Multiple Myeloma
Johnson & Johnson reported an early win in a Phase 3 trial for multiple myeloma, a positive step for its oncology pipeline even though full approval and launch remain further out.
Medium impactLong-term
Veeva Systems Stock: What to Expect From Its Next Earnings Report
Veeva Systems is due to report quarterly results, and the read investors care about is less about a single beat or miss and more about how far along its Vault CRM transition has gotten.
Medium impactShort-term
Elevance Health Stock Holds Steady as Earnings Show Medicaid Growth and Margin Resilience
Elevance Health shares traded in a narrow range after quarterly results pointed to continued Medicaid membership growth and margins that held up despite industrywide cost pressure.
Medium impactShort-term
Eli Lilly Stock: Novo Nordisk Seeks Injunction Over Weight Loss Drug Ads
Novo Nordisk asked a federal court to block specific Eli Lilly ads for Zepbound and Mounjaro, escalating the legal rivalry between the two weight loss drug makers.
Medium impactShort-term
Merck Stock: What the New HIV Pill Licensing Deal Means for MRK
Merck is licensing its experimental HIV pill to generic manufacturers across 129 lower and middle income countries, a global access move with limited direct earnings impact.
Low impactLong-term
Showing 1–16 of 115